$DNA
Ginkgo Bioworks Holdings, Inc. Stock $dna

$dna Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000095017022004821 Filed on March 29, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$148.5M	$313.8M	$32.10M
YoY Change	362.6%	309.4%
Cost Of Revenue	$66.58M	$129.7M	$13.80M
YoY Change	382.45%	730.76%
Gross Profit	$81.92M	$184.1M	$18.20M
YoY Change	350.09%	201.65%
Gross Profit Margin	55.16%	58.68%	56.7%
Selling, General & Admin	$781.6M	$863.0M	$12.90M
YoY Change	5959.12%	2152.79%
% of Gross Profit	954.18%	468.62%	70.88%
Research & Development	$985.0M	$1.150B	$61.20M
YoY Change	1509.52%	619.59%
% of Gross Profit	1202.48%	624.32%	336.26%
Depreciation & Amortization	$8.003M	$26.90M	$4.000M
YoY Change	100.08%	113.49%
% of Gross Profit	9.77%	14.61%	21.98%
Operating Expenses	$1.767B	$2.142B	$74.10M
YoY Change	2284.14%	902.56%
Operating Profit	-$1.685B	-$1.828B	-$55.90M
YoY Change	2913.84%	1234.38%
Interest Expense	-$19.27M	$2.373M	-$600.0K
YoY Change	3111.67%	-0.5%
% of Operating Profit
Other Income/Expense, Net	$98.33M	$80.71M	$10.10M
YoY Change	873.53%	400.51%
Pretax Income	-$1.606B	-$1.838B	-$46.40M
YoY Change	3360.51%	1372.45%
Income Tax	-$683.0K	-$1.480M	$0.00
% Of Pretax Income
Net Earnings	-$1.601B	-$1.830B	-$46.90M
YoY Change	3312.91%	1345.43%
Net Earnings / Revenue	-1077.93%	-583.12%	-146.11%
Basic Earnings Per Share		-$1.35
Diluted Earnings Per Share	-$1.044M	-$1.39	-$0.03
COMMON SHARES
Basic Shares Outstanding		1.360B
Diluted Shares Outstanding		1.360B

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.550B	$1.550B
YoY Change		307.04%
Cash & Equivalents	$1.550B	$1.550B	$380.8M
Short-Term Investments
Other Short-Term Assets	$698.0K	$19.78M	$680.0K
YoY Change	2.65%	5.04%
Inventory	$3.362M	$3.362M	$2.736M
Prepaid Expenses	$9.739M		$9.727M
Receivables	$131.5M	$136.1M	$16.69M
Other Receivables	$13.76M	$13.76M
Total Short-Term Assets	$1.723B	$1.723B	$426.5M
YoY Change	303.96%	303.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$145.8M	$145.8M	$121.4M
YoY Change	20.04%	20.04%
Goodwill	$21.31M		$1.857M
YoY Change	1047.66%		0.0%
Intangibles	$21.64M		$3.294M
YoY Change	557.01%
Long-Term Investments	$13.19M	$115.2M	$28.92M
YoY Change	-54.38%	11.74%
Other Assets	$43.99M	$43.99M	$5.603M
YoY Change	685.12%	685.12%
Total Long-Term Assets	$347.9M	$347.9M	$248.6M
YoY Change	39.96%	39.96%
TOTAL ASSETS
Total Short-Term Assets	$1.723B	$1.723B	$426.5M
Total Long-Term Assets	$347.9M	$347.9M	$248.6M
Total Assets	$2.071B	$2.071B	$675.2M
YoY Change	206.74%	206.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.189M	$8.189M	$13.89M
YoY Change	-41.06%	-41.06%
Accrued Expenses	$93.33M	$93.33M	$30.51M
YoY Change	205.96%	237.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$134.8M	$134.8M	$73.22M
YoY Change	84.05%	84.05%
LONG-TERM LIABILITIES
Long-Term Debt	$22.28M	$22.28M
YoY Change		34.9%
Other Long-Term Liabilities	$35.99M	$346.6M	$3.032M
YoY Change	1087.07%	200.42%
Total Long-Term Liabilities	$35.99M	$368.9M	$3.032M
YoY Change	1087.07%	179.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$134.8M	$134.8M	$73.22M
Total Long-Term Liabilities	$35.99M	$368.9M	$3.032M
Total Liabilities	$503.6M	$565.6M	$205.1M
YoY Change	145.54%	164.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.298B		-$467.9M
YoY Change	391.14%
Common Stock	$161.0K		$129.0K
YoY Change	24.81%		2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.505B	$1.505B	$461.4M
YoY Change
Total Liabilities & Shareholders Equity	$2.071B	$2.071B	$675.2M
YoY Change	206.74%	206.74%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$1.601B	-$1.830B	-$46.90M
YoY Change	3312.91%	1345.43%
Depreciation, Depletion And Amortization	$8.003M	$26.90M	$4.000M
YoY Change	100.08%	113.49%
Cash From Operating Activities	-$165.5M	-$253.8M	-$59.34M
YoY Change	178.97%	86.86%
INVESTING ACTIVITIES
Capital Expenditures	-$5.114M	$56.52M	$19.41M
YoY Change	-126.35%	-2.25%
Acquisitions		$12.04M
YoY Change
Other Investing Activities	$9.342M	-$16.74M	-$9.420M
YoY Change	-199.17%	79.96%
Cash From Investing Activities	$4.228M	-$73.26M	-$28.83M
YoY Change	-114.67%	9.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-11.04M	1.534B	-180.0K
YoY Change	6035.0%	1598.6%
NET CHANGE
Cash From Operating Activities	-165.5M	-253.8M	-59.34M
Cash From Investing Activities	4.228M	-73.26M	-28.83M
Cash From Financing Activities	-11.04M	1.534B	-180.0K
Net Change In Cash	-172.4M	1.207B	-88.35M
YoY Change	95.08%	-1171.67%
FREE CASH FLOW
Cash From Operating Activities	-$165.5M	-$253.8M	-$59.34M
Capital Expenditures	-$5.114M	$56.52M	$19.41M
Free Cash Flow	-$160.4M	-$310.3M	-$78.75M
YoY Change	103.72%	60.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	us-gaap	Depreciation Depreciation	26900000
CY2020	us-gaap	Depreciation Depreciation	12600000
CY2020	dna	Purchase Of Non Cash Marketable Equity Securities PurchaseOfNonCashMarketableEquitySecurities
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019	dna	Purchase Of Non Cash Marketable Equity Securities PurchaseOfNonCashMarketableEquitySecurities
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
CY2020	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity
CY2020Q4	dna	Accrued Product Revenue Accruals AccruedProductRevenueAccruals
CY2019	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1
CY2019	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001830214
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories
CY2019	dna	Proceedsfromloanreceivables Proceedsfromloanreceivables
CY2020	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1
CY2020	dna	Lease Financing Obligation For Build To Suit Lease LeaseFinancingObligationForBuildToSuitLease
CY2021	dei	Entity Bankruptcy Proceedings Reporting Current EntityBankruptcyProceedingsReportingCurrent	true
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
CY2020Q4	dna	Accrued Liability Classified Stock Based Compensation Current AccruedLiabilityClassifiedStockBasedCompensationCurrent
CY2019	dna	Lease Financing Obligation For Build To Suit Lease LeaseFinancingObligationForBuildToSuitLease
CY2020	dna	Proceeds From Reverse Recapitalization Net Of Redemption And Offering Costs ProceedsFromReverseRecapitalizationNetOfRedemptionAndOfferingCosts
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
CY2020	dna	Series E Convertible Preferred Stock Issuance Costs Included In Accrued Expenses SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses
CY2021	dna	Series E Convertible Preferred Stock Issuance Costs Included In Accrued Expenses SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses
CY2020	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dna	Purchase Of Non Marketable Equity Securities PurchaseOfNonMarketableEquitySecurities
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials
CY2020	dna	Purchases Of Equipment Through Capital Leases PurchasesOfEquipmentThroughCapitalLeases
CY2021	dna	Purchases And Issuances Of Loans Receivable PurchasesAndIssuancesOfLoansReceivable
CY2019	us-gaap	Depreciation Depreciation	9600000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess
CY2020	dna	Initial Fair Value Of Warrant Liabilities InitialFairValueOfWarrantLiabilities
CY2021	dna	Purchase Of Loan Receivable From Access Bio Inc PurchaseOfLoanReceivableFromAccessBioInc
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2019	dna	Proceeds From Reverse Recapitalization Net Of Redemption And Offering Costs ProceedsFromReverseRecapitalizationNetOfRedemptionAndOfferingCosts
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet
CY2019	dna	Initial Fair Value Of Warrant Liabilities InitialFairValueOfWarrantLiabilities
CY2020Q4	dna	Accrued Inventory Related Accruals AccruedInventoryRelatedAccruals
CY2020	dna	Equity Received In Related Parties EquityReceivedInRelatedParties
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40097
CY2021	dei	Entity Registrant Name EntityRegistrantName	GINKGO BIOWORKS HOLDINGS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2652913
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	27 Drydock Avenue
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	8th Floor
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02210
CY2021	dei	City Area Code CityAreaCode	877
CY2021	dei	Local Phone Number LocalPhoneNumber	422-5362
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	250500000
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1550004000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	380801000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	131544000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16694000
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	4598000
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	5212000
CY2021Q4	us-gaap	Inventory Net InventoryNet	3362000
CY2020Q4	us-gaap	Inventory Net InventoryNet	2736000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33537000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21099000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1723045000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	426542000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145770000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121435000
CY2021Q4	us-gaap	Investments Investments	102037000
CY2020Q4	us-gaap	Investments Investments	74200000
CY2021Q4	dna	Equity Method Investment EquityMethodInvestment	13194000
CY2020Q4	dna	Equity Method Investment EquityMethodInvestment	28924000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21642000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3294000
CY2021Q4	us-gaap	Goodwill Goodwill	21312000
CY2020Q4	us-gaap	Goodwill Goodwill	1857000
CY2021Q4	dna	Loans Receivable Net Of Current Portion LoansReceivableNetOfCurrentPortion	0
CY2020Q4	dna	Loans Receivable Net Of Current Portion LoansReceivableNetOfCurrentPortion	13298000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	43990000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5603000
CY2021Q4	us-gaap	Assets Assets	2070990000
CY2020Q4	us-gaap	Assets Assets	675153000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8189000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13893000
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	12502000
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	22101000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33240000
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	28823000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	93332000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	30505000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	134761000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	73221000
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	18746000
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	12678000
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	148319000
CY2020Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	97977000
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	155991000
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	99652000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22283000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	16518000
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	135838000
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	35992000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3032000
CY2021Q4	us-gaap	Liabilities Liabilities	503611000
CY2020Q4	us-gaap	Liabilities Liabilities	205101000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15800000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15800000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1690990815
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1289014925
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1611392152
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1288595876
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	161000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	129000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3804844000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	929125000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2297925000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467878000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1715000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1505365000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	461376000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	62014000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	8676000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1567379000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	470052000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2070990000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	675153000
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	47161000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	42535000
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	35268000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	313837000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76657000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54184000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1149662000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	159767000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	96299000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	862952000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38306000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29483000
CY2021	us-gaap	Operating Expenses OperatingExpenses	2142304000
CY2020	us-gaap	Operating Expenses OperatingExpenses	213684000
CY2019	us-gaap	Operating Expenses OperatingExpenses	125782000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1828467000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-137027000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-71598000
CY2021	us-gaap	Interest Income Other InterestIncomeOther	837000
CY2020	us-gaap	Interest Income Other InterestIncomeOther	2582000
CY2019	us-gaap	Interest Income Other InterestIncomeOther	5756000
CY2021	us-gaap	Interest Expense InterestExpense	2373000
CY2020	us-gaap	Interest Expense InterestExpense	2385000
CY2019	us-gaap	Interest Expense InterestExpense	2421000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-77284000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-396000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-27533000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-11543000
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-3733000
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments	-27200000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-58615000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2021	dna	Gain On Settlement Of Partnership Agreement GainOnSettlementOfPartnershipAgreement	23826000
CY2020	dna	Gain On Settlement Of Partnership Agreement GainOnSettlementOfPartnershipAgreement	8286000
CY2019	dna	Gain On Settlement Of Partnership Agreement GainOnSettlementOfPartnershipAgreement	1587000
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1733000
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7839000
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1574000
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9655000
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	12193000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-48237000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1838122000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-124834000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-119835000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1480000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1889000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000
CY2021	us-gaap	Profit Loss ProfitLoss	-1836642000
CY2020	us-gaap	Profit Loss ProfitLoss	-126723000
CY2019	us-gaap	Profit Loss ProfitLoss	-119857000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6595000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-114000
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-530000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1830047000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-126609000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-119327000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.39
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1359848803
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1274766915
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1149000417
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1360373343
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1274766915
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1149000417
CY2021	us-gaap	Profit Loss ProfitLoss	-1836642000
CY2020	us-gaap	Profit Loss ProfitLoss	-126723000
CY2019	us-gaap	Profit Loss ProfitLoss	-119857000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1715000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1715000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1838357000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-126723000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119857000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4830000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	213432000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4830000
CY2019	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	12651000
CY2019	dna	Conversion Of Convertible Promissory Notes Into Convertible Preferred Stock Value ConversionOfConvertiblePromissoryNotesIntoConvertiblePreferredStockValue	211608000
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	408000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	150000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	771000
CY2019	us-gaap	Profit Loss ProfitLoss	-119857000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	501853000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	476000
CY2020	us-gaap	Profit Loss ProfitLoss	-126723000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	470052000
CY2021	dna	Issuance Of Common Stock Options Value And Vesting Of Restricted Stock Units IssuanceOfCommonStockOptionsValueAndVestingOfRestrictedStockUnits	176000
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-9463000
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	24998000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	300000
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	15160000
CY2021	dna	Issuance Of Common Stock Value Upon Reverse Recapitalization Net Of Offering Costs IssuanceOfCommonStockValueUponReverseRecapitalizationNetOfOfferingCosts	1509629000
CY2021	dna	Assumption Of Public And Private Placement Warrants AssumptionOfPublicAndPrivatePlacementWarrants	-194453000
CY2021	dna	Non Controlling Interest Contributions NonControllingInterestContributions	59933000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1579400000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1715000
CY2021	us-gaap	Profit Loss ProfitLoss	-1836642000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1567379000
CY2021	us-gaap	Profit Loss ProfitLoss	-1836642000
CY2020	us-gaap	Profit Loss ProfitLoss	-126723000
CY2019	us-gaap	Profit Loss ProfitLoss	-119857000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	29076000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13864000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10755000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1606020000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	476000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	771000
CY2021	dna	Non Cash Equity Consideration NonCashEquityConsideration	-24185000
CY2020	dna	Non Cash Equity Consideration NonCashEquityConsideration	0
CY2019	dna	Non Cash Equity Consideration NonCashEquityConsideration	0
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-77284000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-396000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-27533000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-11543000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-11543000
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-3733000
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments	-27200000
CY2021	dna	Changes In Fair Value Of Loans Receivable ChangesInFairValueOfLoansReceivable	3508000
CY2020	dna	Changes In Fair Value Of Loans Receivable ChangesInFairValueOfLoansReceivable	-1061000
CY2019	dna	Changes In Fair Value Of Loans Receivable ChangesInFairValueOfLoansReceivable	-914000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-58615000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	270000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	728000
CY2021	dna	Accounts Receivable From Related Parties AccountsReceivableFromRelatedParties	614000
CY2020	dna	Accounts Receivable From Related Parties AccountsReceivableFromRelatedParties	-995000
CY2019	dna	Accounts Receivable From Related Parties AccountsReceivableFromRelatedParties	-2221000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	114094000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14228000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1843000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2981000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11352000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4031000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	626000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2736000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	539000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1834000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2361000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2247000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7019000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	664000
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	44796000
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	8665000
CY2019	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	4170000
CY2021	dna	Deferred Revenue From Related Parties DeferredRevenueFromRelatedParties	40743000
CY2020	dna	Deferred Revenue From Related Parties DeferredRevenueFromRelatedParties	-22253000
CY2019	dna	Deferred Revenue From Related Parties DeferredRevenueFromRelatedParties	3112000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10498000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-19423000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4883000
CY2021	us-gaap	Straight Line Rent StraightLineRent	-6032000
CY2020	us-gaap	Straight Line Rent StraightLineRent	-1045000
CY2019	us-gaap	Straight Line Rent StraightLineRent	-9095000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	18620000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2661000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-253818000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-135830000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44663000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56521000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57821000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22219000
CY2020	dna	Purchase Of Loan Receivable From Access Bio Inc PurchaseOfLoanReceivableFromAccessBioInc	10100000
CY2019	dna	Purchase Of Loan Receivable From Access Bio Inc PurchaseOfLoanReceivableFromAccessBioInc	2250000
CY2021	dna	Proceedsfromloanreceivables Proceedsfromloanreceivables	304000
CY2020	dna	Proceedsfromloanreceivables Proceedsfromloanreceivables	800000
CY2021	dna	Purchase Of Non Marketable Equity Securities PurchaseOfNonMarketableEquitySecurities	5000000
CY2019	dna	Purchase Of Non Marketable Equity Securities PurchaseOfNonMarketableEquitySecurities	50133000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	12040000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73257000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67121000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74602000
CY2021	dna	Recapitalization Redemption Amounts RecapitalizationRedemptionAmounts	867253000
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	108118000
CY2021	dna	Proceeds From Reverse Recapitalization Net Of Redemption And Offering Costs ProceedsFromReverseRecapitalizationNetOfRedemptionAndOfferingCosts	1509629000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	167000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000
CY2021	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	24998000
CY2019	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	408000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9463000
CY2021	dna	Principal Payments On Capital Leases And Lease Financing Obligation PrincipalPaymentsOnCapitalLeasesAndLeaseFinancingObligation	1123000
CY2020	dna	Principal Payments On Capital Leases And Lease Financing Obligation PrincipalPaymentsOnCapitalLeasesAndLeaseFinancingObligation	748000
CY2019	dna	Principal Payments On Capital Leases And Lease Financing Obligation PrincipalPaymentsOnCapitalLeasesAndLeaseFinancingObligation	828000
CY2021	dna	Proceeds From Lease Financing Obligation ProceedsFromLeaseFinancingObligation	0
CY2020	dna	Proceeds From Lease Financing Obligation ProceedsFromLeaseFinancingObligation	0
CY2019	dna	Proceeds From Lease Financing Obligation ProceedsFromLeaseFinancingObligation	476000
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	59933000
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2019	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	198957000
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	91040000
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	212181000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1534145000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	90318000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	410385000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-19000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1207051000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-112633000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	291120000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	385877000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	498510000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207390000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1592928000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	385877000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	498510000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2370000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2572000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2348000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	61000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	31000
CY2021	dna	Purchases Of Equipment Through Capital Leases PurchasesOfEquipmentThroughCapitalLeases	1981000
CY2019	dna	Purchases Of Equipment Through Capital Leases PurchasesOfEquipmentThroughCapitalLeases	406000
CY2021	dna	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	1815000
CY2020	dna	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	14458000
CY2019	dna	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	605000
CY2021	dna	Equity Received In Related Parties EquityReceivedInRelatedParties	61554000
CY2019	dna	Equity Received In Related Parties EquityReceivedInRelatedParties	24480000
CY2021	dna	Purchase Of Non Cash Marketable Equity Securities PurchaseOfNonCashMarketableEquitySecurities	10000000
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	15087000
CY2021	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	8760000
CY2020	dna	Purchases And Issuances Of Loans Receivable PurchasesAndIssuancesOfLoansReceivable	375000
CY2019	dna	Purchases And Issuances Of Loans Receivable PurchasesAndIssuancesOfLoansReceivable	2744000
CY2021	dna	Initial Fair Value Of Warrant Liabilities InitialFairValueOfWarrantLiabilities	194453000
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	195000
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	211608000
CY2019	dna	Series E Convertible Preferred Stock Issuance Costs Included In Accrued Expenses SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses	3380000
CY2021	dna	Lease Financing Obligation For Build To Suit Lease LeaseFinancingObligationForBuildToSuitLease	6120000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1550004000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	380801000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	495287000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	42924000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5076000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	3223000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1592928000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	385877000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	498510000
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reclassifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions used in preparation of these consolidated financial statements include, among others, those related to the fair value of equity instruments and equity awards, revenue recognition, the fair value of loans receivable, the fair value of certain investments, including equity method investments, the fair value of warrant liabilities, accrued expenses, and income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Reported amounts and disclosures reflect the overall economic conditions that management believes are most likely to occur, and the anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, accounts receivable, and loans receivable. The Company’s cash and cash equivalents and restricted cash are</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> maintained in bank deposit accounts and money market funds that regularly exceed federally insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held in financial institutions that management believes to be of high credit quality. The Company’s accounts receivable primarily consists of amounts due under its Biosecurity contracts; however, concentrations of credit risk associated with these contracts are limited because the customer base is largely made up of state government agencies. The Company has not experienced any material write-offs related to its accounts receivable since inception.</span></p>
CY2021	dna	Schedule Of Estimated Lives Of Property And Equipment ScheduleOfEstimatedLivesOfPropertyAndEquipment	<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimated lives of property and equipment are as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.058%;"/> <td style="width:46.942%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimated Useful Life</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 5 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Facilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vehicles</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or remaining lease term</span></span></p></td> </tr> </table>
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2020	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2019	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2020	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2019	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	dna	Deferred Rent DeferredRent	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Rent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred rent consists of the difference between cash paid and rent expense recognized on a straight-line basis for the facilities that the Company occupies under operating leases. The Company classifies the current portion of the deferred rent balance as a component of accrued expenses and other current liabilities on the Consolidated Balance Sheets.</span>
CY2021	dna	Patent Costs PatentCosts	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses all costs as incurred in connection with the filing, prosecution, maintenance, defense, and enforcement of patent applications, including direct application fees and related legal and consulting expenses. Patent costs are included in general and administrative expenses within the Consolidated Statements of Operations and Comprehensive Loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	dna	Accrued Interest And Penalties AccruedInterestAndPenalties	0
CY2020Q4	dna	Accrued Interest And Penalties AccruedInterestAndPenalties	0
CY2021Q3	dna	Shares Exchange Ratio SharesExchangeRatio	49.080452
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Share Price SharePrice	12.50
CY2021Q4	dna	Earnout Shares Vested And Outstanding EarnoutSharesVestedAndOutstanding	38800000
CY2021	dna	Other Offering Costs OtherOfferingCosts	-108118000
CY2021	dna	Net Proceeds From Business Acquisition NetProceedsFromBusinessAcquisition	1509629000
CY2021	dna	Fair Value Of Consideration Transferred FairValueOfConsiderationTransferred	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the preliminary acquisition date fair value of the consideration transferred for Dutch DNA (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.294%;"/> <td style="width:1.927%;"/> <td style="width:1.814%;"/> <td style="width:16.057%;"/> <td style="width:0.907%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,451</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of Class A common stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,087</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,760</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Dutch DNA consideration</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,298</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table>
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
CY2020	dna	Conversion Discount Percentage ConversionDiscountPercentage	0.20
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.855
CY2021	dna	Years To Maturity YearsToMaturity	P0Y10M17D
CY2021	dna	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Adjsuted Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskAdjsutedInterestRate	3090
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	dna	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountRate	0.328
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.885
CY2021Q4	us-gaap	Investments Investments	102037000
CY2020Q4	us-gaap	Investments Investments	74200000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	13194000
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	28924000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	20000000.0
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9739000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9727000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	9199000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1127000
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-3733000
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments	-27200000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-77284000
CY2021Q4	dna	Prepaid Inventory Current PrepaidInventoryCurrent	144000
CY2020Q4	dna	Prepaid Inventory Current PrepaidInventoryCurrent	6536000
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	11559000
CY2020Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	2268000
CY2021Q4	us-gaap	Other Receivables OtherReceivables	2198000
CY2020Q4	us-gaap	Other Receivables OtherReceivables	761000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	698000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	680000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33537000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21099000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3264000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2756000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	64000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	50000
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	16000
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	20000
CY2021Q4	us-gaap	Inventory Net InventoryNet	3362000
CY2020Q4	us-gaap	Inventory Net InventoryNet	2736000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	206822000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	155213000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61052000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33778000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145770000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121435000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-396000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3037000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	14871000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-27533000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6381000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	1800000
CY2020Q4	us-gaap	Goodwill Goodwill	1857000
CY2019Q4	us-gaap	Goodwill Goodwill	1857000
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	15177000
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0
CY2021	dna	Goodwill Measurement Period Adjustment GoodwillMeasurementPeriodAdjustment	5000000
CY2020	dna	Goodwill Measurement Period Adjustment GoodwillMeasurementPeriodAdjustment	0
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-722000
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-0
CY2021Q4	us-gaap	Goodwill Goodwill	21312000
CY2020Q4	us-gaap	Goodwill Goodwill	1857000
CY2021	us-gaap	Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	900000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3650000
CY2021Q4	dna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	991000
CY2020Q4	dna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	10017000
CY2021Q4	dna	Accrued Product Revenue Accruals AccruedProductRevenueAccruals	4565000
CY2021Q4	dna	Accrued Biosecurity Service Revenue Accruals Current AccruedBiosecurityServiceRevenueAccrualsCurrent	28726000
CY2020Q4	dna	Accrued Biosecurity Service Revenue Accruals Current AccruedBiosecurityServiceRevenueAccrualsCurrent	1440000
CY2021Q4	dna	Accrued Inventory Related Accruals AccruedInventoryRelatedAccruals	3538000
CY2021Q4	dna	Accrued Lab Supplies Current AccruedLabSuppliesCurrent	560000
CY2020Q4	dna	Accrued Lab Supplies Current AccruedLabSuppliesCurrent	4276000
CY2021Q4	dna	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	11000
CY2020Q4	dna	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	2594000
CY2021Q4	dna	Accrued Liability Classified Stock Based Compensation Current AccruedLiabilityClassifiedStockBasedCompensationCurrent	26612000
CY2021Q4	dna	Accrued Capital Lease Obligation Current AccruedCapitalLeaseObligationCurrent	747000
CY2020Q4	dna	Accrued Capital Lease Obligation Current AccruedCapitalLeaseObligationCurrent	485000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9061000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2275000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	93332000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30505000
CY2021Q4	dna	Number Of Properties Subject To Operating Lease Occupied By The Company NumberOfPropertiesSubjectToOperatingLeaseOccupiedByTheCompany	2
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	20600000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	22505000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	33469000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	47376000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	44092000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	517399000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	685441000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	6100000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	816000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	681000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	438000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	163000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	2098000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	127000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	1971000
CY2021Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	99000000
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021	dna	Number Of Trading Days To Determine Call Of Warrant Redemption NumberOfTradingDaysToDetermineCallOfWarrantRedemption	P30D
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15800000000
CY2021	us-gaap	Dividends Dividends	0
CY2021	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. Generally, shares of Class B common stock will convert automatically into Class A common stock upon the holder ceasing to be an Eligible Holder (i.e., director, employee, trust or legal entity of New Ginkgo), unless otherwise determined by affirmative vote of a majority of independent directors of New Ginkgo.
CY2019Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	490805
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	100000
CY2021Q4	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	0
CY2020Q4	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	0
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	465945709
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33354871
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.02
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1664251
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.50
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10969639
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.02
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1594820
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.02
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22454663
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y3M25D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	185620000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	22385232
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.02
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y3M18D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	185620000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	91000000.0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5300000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1100000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.97
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0011
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.886
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y11M15D
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Year1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1	2026
CY2021	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	6400000
CY2021	dna	Number Of Additional Common Units Received NumberOfAdditionalCommonUnitsReceived	7245000
CY2021	dna	Number Of Allocated Performance Obligations NumberOfAllocatedPerformanceObligations	10
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3700000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2200000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1600000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1682565000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	476000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	771000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	500000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2021	dna	Foundry Revenue Percentage FoundryRevenuePercentage	1
CY2020	dna	Foundry Revenue Percentage FoundryRevenuePercentage	1
CY2019	dna	Foundry Revenue Percentage FoundryRevenuePercentage	1
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	128500000
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	28800000
CY2019Q4	us-gaap	Deferred Revenue DeferredRevenue	147900000
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	25500000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	21100000
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	20700000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Year1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1	2022
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1837497000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-124834000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-119835000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-625000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1838122000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-124834000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-119835000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	26000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	22000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-413000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	581000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-912000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1282000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-156000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1480000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1889000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.045
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.045
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.042
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.239
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.313
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.252
CY2021	dna	Executive Compensation ExecutiveCompensation	-0.020
CY2020	dna	Executive Compensation ExecutiveCompensation	0
CY2020	dna	Effective Income Tax Rate Reconciliation Equity Investments1 EffectiveIncomeTaxRateReconciliationEquityInvestments1	-0.006
CY2019	dna	Effective Income Tax Rate Reconciliation Equity Investments1 EffectiveIncomeTaxRateReconciliationEquityInvestments1	-0.057
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.048
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.044
CY2021	dna	Effective Income Tax Rate Reconciliation Nondeductible Expense And Change In Fair Value Of Warrant Liability Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAndChangeInFairValueOfWarrantLiabilityPercent	0.009
CY2019	dna	Executive Compensation ExecutiveCompensation	0
CY2021	dna	Effective Income Tax Rate Reconciliation Equity Investments1 EffectiveIncomeTaxRateReconciliationEquityInvestments1	-0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.014
CY2020	dna	Effective Income Tax Rate Reconciliation Nondeductible Expense And Change In Fair Value Of Warrant Liability Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAndChangeInFairValueOfWarrantLiabilityPercent	-0.002
CY2019	dna	Effective Income Tax Rate Reconciliation Nondeductible Expense And Change In Fair Value Of Warrant Liability Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAndChangeInFairValueOfWarrantLiabilityPercent	-0.001
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.015
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	174127000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	91467000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	37455000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	20338000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2690000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1265000
CY2021Q4	dna	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	45928000
CY2020Q4	dna	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	28590000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	318049000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0
CY2021Q4	dna	Deferred Tax Assets Amortizable Intangibles DeferredTaxAssetsAmortizableIntangibles	3834000
CY2020Q4	dna	Deferred Tax Assets Amortizable Intangibles DeferredTaxAssetsAmortizableIntangibles	4198000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	2927000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	2206000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	585010000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	148064000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	583107000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	143827000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1903000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4237000
CY2021Q4	dna	Deferred Tax Liabilities Amortizable Intangibles DeferredTaxLiabilitiesAmortizableIntangibles	4722000
CY2020Q4	dna	Deferred Tax Liabilities Amortizable Intangibles DeferredTaxLiabilitiesAmortizableIntangibles	0
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	830000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	830000
CY2021Q4	dna	Deferred Tax Liabilities Basis Differences DeferredTaxLiabilitiesBasisDifferences	1522000
CY2020Q4	dna	Deferred Tax Liabilities Basis Differences DeferredTaxLiabilitiesBasisDifferences	5270000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7074000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6100000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5171000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1863000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	143827000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	439280000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	583107000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	104745000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	39082000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	143827000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	439300000
CY2021	dna	Percentage Of Stockholders Determining Cumulative Change In Ownership PercentageOfStockholdersDeterminingCumulativeChangeInOwnership	0.05
CY2021	dna	Percentage Points Used In Determining Cumulative Change In Ownership PercentagePointsUsedInDeterminingCumulativeChangeInOwnership	0.50
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-1830047000
CY2020	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-126609000
CY2019	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-119327000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-58615000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-1888662000
CY2020	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-126609000
CY2019	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-119327000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1359848803
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1274766915
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1149000417
CY2021	dna	Weighted Average Effect Of Dilutive Outstanding Warrants WeightedAverageEffectOfDilutiveOutstandingWarrants	524540
CY2020	dna	Weighted Average Effect Of Dilutive Outstanding Warrants WeightedAverageEffectOfDilutiveOutstandingWarrants	0
CY2019	dna	Weighted Average Effect Of Dilutive Outstanding Warrants WeightedAverageEffectOfDilutiveOutstandingWarrants	0
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1360373343
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1274766915
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1149000417
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.39
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	354728664
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	159726314
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	107092830
CY2021Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	4598000
CY2020Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	5212000
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	47161000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	42535000
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	35268000

Files In Submission

Name	View Source	Status
0000950170-22-004821-index-headers.html	Edgar Link	pending
0000950170-22-004821-index.html	Edgar Link	pending
0000950170-22-004821.txt	Edgar Link	pending
0000950170-22-004821-xbrl.zip	Edgar Link	pending
dna-20211231.htm	Edgar Link	pending
dna-20211231.xsd	Edgar Link	pending
dna-20211231_cal.xml	Edgar Link	unprocessable
dna-20211231_def.xml	Edgar Link	unprocessable
dna-20211231_htm.xml	Edgar Link	completed
dna-20211231_lab.xml	Edgar Link	unprocessable
dna-20211231_pre.xml	Edgar Link	unprocessable
dna-ex23_1.htm	Edgar Link	pending
dna-ex31_1.htm	Edgar Link	pending
dna-ex31_2.htm	Edgar Link	pending
dna-ex32_1.htm	Edgar Link	pending
dna-ex32_2.htm	Edgar Link	pending
dna-ex4_2.htm	Edgar Link	pending
dna-ex4_4.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img147226290_0.jpg	Edgar Link	pending
img147226290_1.jpg	Edgar Link	pending
img147226290_10.jpg	Edgar Link	pending
img147226290_11.jpg	Edgar Link	pending
img147226290_12.jpg	Edgar Link	pending
img147226290_13.jpg	Edgar Link	pending
img147226290_14.jpg	Edgar Link	pending
img147226290_15.jpg	Edgar Link	pending
img147226290_16.jpg	Edgar Link	pending
img147226290_17.jpg	Edgar Link	pending
img147226290_18.jpg	Edgar Link	pending
img147226290_19.jpg	Edgar Link	pending
img147226290_2.jpg	Edgar Link	pending
img147226290_3.jpg	Edgar Link	pending
img147226290_4.jpg	Edgar Link	pending
img147226290_5.jpg	Edgar Link	pending
img147226290_6.jpg	Edgar Link	pending
img147226290_7.jpg	Edgar Link	pending
img147226290_8.jpg	Edgar Link	pending
img147226290_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DNA
Ginkgo Bioworks Holdings, Inc. Stock $dna

2021 Q4 Form 10-K Financial Statement

#000095017022004821 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNA Ginkgo Bioworks Holdings, Inc. Stock $dna

2021 Q4 Form 10-K Financial Statement

#000095017022004821 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNA
Ginkgo Bioworks Holdings, Inc. Stock $dna